Role of the PPARГ Proi2Ala polymorphism in hypertension and metabolic syndrome

Aim. То study prevalence of Pro12Ala polymorphism of the PPARγ gene in Uzbek hypertensive patients and healthy men and its association with blood pressure and cardiovascular remodeling process. Methods. We observed 169 hypertensive patients and 50 healthy men Uzbek nationality. Metabolic syndrome (MS) was defined according to IDF, 2005. It has been performed oral glucose tolerance test, echocardiography, reactive hyperemia test, definition of common carotid intima-media thickness, lipids, microalbuminuria (MAU). Genotyping of Pro12Ala polymorphism of the PPARγ gene was determined by PCR amplification with allele-specific primers. Results. Analysis of frequency distribution of Pro12Ala polymorphism of the PPARγ gene has shown significantly greater accumulation of Proallele both among hypertensive patients (89.9%) and healthy subjects (83%). There was no association between Pro12Ala polymorphism of the PPARγ gene and blood pressure, left ventricular mass lipid and glucose levels in hypertensive patients with MS. It has been revealed higher heart rate and MAU in hypertensive patients with MS-carriers of Proallele as compared with Ala-allele carriers. Genetic risk assessment of MS by multiplicative model of inheritance has shown that availability of Pro-allele has associated with high risk of MS (OR 1.73, 95%CI 0.84-3.37) but presence of Ala-allele has associated with low risk of MS (OR 0.58 95%CI 0.30-1.13). Conclusion. It has been found high frequency of Pro-allele and Pro/Pro genotype of Pro12Ala polymorphism of the PPARγ gene both among hypertensive patients with or without MS and healthy subjects of Uzbek nationality. Probability of MS development is higher in hypertensive patients with MS-carriers of Pro-allele of Pro12Ala polymorphism of the PPARγ gene as compared with Ala-allele carriers.